SYTE.bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

SYTE.bio is a private, clinical-stage biotech leveraging synthetic biology to create non-viral DNA and RNA therapeutics and vaccines for human and animal health. The company has advanced its lead animal oncology program, INVIVO-mAb Anti CTLA4, into Phase III trials, demonstrating progress in its pipeline. With a dual-platform technology strategy and a focus on safety and efficacy, SYTE.bio aims to address unmet needs in areas like oncology, chronic diseases, and infectious diseases. The company operates with a global footprint, including offices in Boston and Buenos Aires.

OncologyInfectious DiseaseChronic DiseasePainDermatologyVeterinary Health

Technology Platform

Proprietary non-viral DNA and RNA platforms for in vivo production of therapeutic proteins and antigens. DNA for durable, long-term expression; RNA for transient, rapid expression. Platforms are modular, allowing tailored expression timelines and combination with adjuvants.

Opportunities

The validated success of mRNA vaccines opens a large market for RNA and DNA-based therapies in both human and animal health.

SYTE.bio's advanced veterinary oncology pipeline provides a near-term potential revenue path and platform validation that could de-risk its human health ambitions.

The growing demand for advanced biologics in pet care and the need for rapid-response vaccine platforms against emerging pathogens represent significant addressable markets.

Risk Factors

The company faces intense competition from well-funded players in the nucleic acid therapeutics space and must prove the efficacy and safety of its non-viral delivery platforms.

As a pre-revenue, private company, it is highly dependent on external financing to advance its costly clinical programs.

Technical hurdles in efficient non-viral delivery and manufacturing scalability present significant development risks.

Competitive Landscape

SYTE.bio competes in the crowded nucleic acid therapeutics arena against large mRNA players (Moderna, BioNTech), DNA vaccine developers (Inovio), and numerous gene therapy companies. In animal health, it competes with established veterinary pharma companies and biotechs like Zoetis and Elanco, as well as startups developing immunotherapies for pets. Its differentiation lies in its dual DNA/RNA platform and focus on in vivo antibody production.

More companies in United States →